Ann: FirstFlow Burette market update , page-8

jessie1

domestically that may be the case, but wegian's comment "MLA is a much better investment" and that it is a 50/50 is naive and incorrect

MLA have the right I believe to Australia and New Zealand, and it appears the UK - WiseOwl reported these markets to be around $88M (have to check whether includes UK)

Would you rather invest in the company that is pursuing the $88M market from the distributor's perspective or the company that owns the product and is targeting to license it in the $3Bn market.

Australia and New Zealand is only miniscule on the world scale.

As I said earlier, if ALT secures any HOA or deal in the US and Latin America with one of the 'majors' they have eluded to, MLA receive nothing. These are multi $Bn companies and multi $Bn markets.

I do not for one second see ALT's end goal as wrapping up the domestic market - it always has been securing an international distributor such as J&J or Baxter who have distribution channels into nearly every country in the world and letting them do the heavy lifting.

Also, licensing the product comes at a significantly reduced risk as they do not have to worry about raising cash to meet production, logistics etc - i.e leave it to the experts

If domestically they secure QLD Health it will mean great things for both companies. However, ALT have announced they are in discussions with a major in the US and making encouraging progress in Latin America - huge markets, huge potential - solely ALT's reward